var title_f1_43_1712="Avulsion anterior iliac spine";
var content_f1_43_1712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apophyseal avulsion injury of the right anterior superior iliac spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apophyseal avulsion injury of the right anterior superior iliac spine at the site of insertion of the sartorius (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rajvee Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1712=[""].join("\n");
var outline_f1_43_1712=null;
var title_f1_43_1713="Pulmonary mucormycosis";
var content_f1_43_1713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary mucormycosis in a lung transplant recipient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Computed tomography (CT) scan of lung showing pulmonary nodule and (B) fine needle aspiration of right lower lobe of lung showing aseptate hyphae (Papanicolaou stain, x400).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1713=[""].join("\n");
var outline_f1_43_1713=null;
var title_f1_43_1714="Patient information: Rectal prolapse in children (The Basics)";
var content_f1_43_1714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83753\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\">",
"         Diagram of the colon and rectum",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/2/43041\">",
"         Patient information: Constipation in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/57/20371\">",
"         Patient information: Cystic fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rectal prolapse in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rectal-prolapse-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9656400\">",
"      <span class=\"h1\">",
"       What is rectal prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rectal prolapse is a condition that happens when some or all of the tissue that lines the rectum sticks out of the anus (",
"      <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      It is most common in babies and children younger than 4 who also have another health problem. The most common problems are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Constipation &ndash; This means the child&rsquo;s bowel movements:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Are too hard",
"       </li>",
"       <li>",
"        Are difficult to get out",
"       </li>",
"       <li>",
"        Happen fewer than 3 times a week",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Diarrhea - This means the child&rsquo;s bowel movements:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Are watery or runny",
"       </li>",
"       <li>",
"        Happen more than 3 times a day",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with the brain or spinal cord &ndash; The spinal cord is the highway of nerves that connects the brain to the rest of the body. It runs through the spine (also called the backbone). These problems can cause weak muscles and affect the muscles near the rectum. Conditions that can lead to rectal prolapse include: &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Spina bifida - This condition happens when a baby&rsquo;s spine does not grow normally before birth.",
"       </li>",
"       <li>",
"        Brain and spinal cord injuries &ndash; These are usually caused by bad car crashes or falls.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cystic fibrosis &ndash; This disease causes thick mucus and other fluids to build up and clog different parts of the body. Children with cystic fibrosis can have frequent lung infections. They also can have large, bulky bowel movements.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9656415\">",
"      <span class=\"h1\">",
"       What are the symptoms of rectal prolapse in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is bright red tissue sticking out of the anus. The tissue might have mucus or blood. Rectal prolapse is not usually painful but can be uncomfortable. The tissue might stay outside the anus or move back inside the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9656430\">",
"      <span class=\"h1\">",
"       Is there a test for rectal prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your child&rsquo;s doctor or nurse should be able to tell if your child has the condition by doing an exam. If the tissue has moved back inside your child&rsquo;s body, you can describe the tissue to the doctor. This can help the doctor know if the child has rectal prolapse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9656445\">",
"      <span class=\"h1\">",
"       How is rectal prolapse treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor will push the rectal tissue back into the child&rsquo;s anus with a gloved finger. Some children need medicines to make them relaxed and sleepy before the doctor does this. The doctor can also teach parents how to push the tissue back if it comes out again.",
"     </p>",
"     <p>",
"      If this treatment does not work or the problem keeps coming back, the child might need surgery.",
"     </p>",
"     <p>",
"      Other treatments can help prevent rectal prolapse from happening again. The treatment depends on what caused the prolapse the first time.",
"     </p>",
"     <p>",
"      A child who is constipated and has rectal prolapse should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat a diet that has lots of fruits and vegetables",
"       </li>",
"       <li>",
"        Sit on the toilet for 5 or 10 minutes after meals, if he or she is potty trained. Parents can give rewards just for sitting there.",
"       </li>",
"       <li>",
"        Stop potty training for a while, if he or she is in the middle of potty training",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor might also give your child medicines that soften bowel movements, such as PEG (sample brand name: MiraLAX&reg;).",
"     </p>",
"     <p>",
"      Children with diarrhea need treatment for the cause of the diarrhea. Most of the time, diarrhea is caused by an infection or is a side effect from a medicine.",
"     </p>",
"     <p>",
"      Children with rectal prolapse who do not have an obvious cause should be tested for cystic fibrosis. Children who already have cystic fibrosis can take medicines called &ldquo;pancreatic enzymes.&rdquo; These help make the child&rsquo;s bowel movements more regular.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9656460\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=see_link\">",
"       Patient information: Constipation in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       Patient information: Cystic fibrosis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/43/1714?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83753 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1714=[""].join("\n");
var outline_f1_43_1714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9656400\">",
"      What is rectal prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9656415\">",
"      What are the symptoms of rectal prolapse in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9656430\">",
"      Is there a test for rectal prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9656445\">",
"      How is rectal prolapse treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9656460\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\">",
"      Diagram of the colon and rectum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1715="Early postpneumonectomy PA";
var content_f1_43_1715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72520%7EPULM%2F75963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72520%7EPULM%2F75963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expected chest radiographic changes in the early postpneumonectomy period",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immediately after surgery, a chest tube is in place, the postpneumonectomy space (arrow) is empty, and the ipsilateral hemidiaphragm is slightly elevated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expected chest radiographic changes in the early postpneumonectomy period",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forty-eight hours after surgery, fluid has quickly accumulated in the postpneumonectomy space after removal of the chest tube. Note the shift in the trachea towards the operative side (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1715=[""].join("\n");
var outline_f1_43_1715=null;
var title_f1_43_1716="Gallium nitrate: Patient drug information";
var content_f1_43_1716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gallium nitrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"     see \"Gallium nitrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ganite&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor if you have kidney disease. Check all drugs with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gallium nitrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor kidney function.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10804 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1716=[""].join("\n");
var outline_f1_43_1716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175242\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021296\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021298\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021297\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021302\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021303\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021305\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021300\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021301\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021306\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021307\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=related_link\">",
"      Gallium nitrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1717="Domperidone: Drug information";
var content_f1_43_1717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Domperidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18516?source=see_link\">",
"    see \"Domperidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Domperidone&reg;;",
"     </li>",
"     <li>",
"      Dom-Domperidone;",
"     </li>",
"     <li>",
"      Mylan-Domperidone;",
"     </li>",
"     <li>",
"      Nu-Domperidone;",
"     </li>",
"     <li>",
"      PHL-Domperidone;",
"     </li>",
"     <li>",
"      PMS-Domperidone;",
"     </li>",
"     <li>",
"      RAN&trade;-Domperidone;",
"     </li>",
"     <li>",
"      ratio-Domperidone;",
"     </li>",
"     <li>",
"      Teva-Domperidone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dopamine Antagonist;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Prokinetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GI motility disorders:",
"     </b>",
"     Oral: Usual: 10 mg 3-4 times/day, 15-30 minutes before meals and at bedtime if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe/resistant cases:",
"     </i>",
"     May increase to maximum dose of 20 mg 3-4 times/day, 15-30 minutes before meals and at bedtime if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents:",
"     </b>",
"     Oral: Usual: 20 mg 3-4 times/day (higher doses may be necessary during titration of anti-Parkinson therapy)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F162496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (serum creatinine &gt;0.6 mmol/L): Reduce dosing frequency to 1-2 times/day with prolonged therapy. Dose reduction may also be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10869539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Use with caution; undergoes hepatic metabolism. The manufacturer's  labeling does not provide specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg [domperidone maleate 12.72 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Apo-Domperidone&reg;, Dom-Domperidone, Novo-Domperidone,  Nu-Domperidone, PHL-Domperidone, PMS-Domperidone, ratio-Domperidone: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13841022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Domperidone is available via an Investigational New Drug Application (IND) in the United States for severe GI disorders refractory to standard therapy. For more information on the requirements for the IND, contact the Food and Drug Administration (FDA) at 301-796-3400.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F162472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In GI motility disorders, administer 15-30 minutes prior to meals and at bedtime if needed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis; prevention of GI symptoms associated with use of dopamine-agonist anti-Parkinson agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9770161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Domperidone may be confused with iloperidone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache/migraine (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): ALT increased, AST increased, dizziness, dysuria, edema, extrapyramidal symptoms (EPS) rarely, galactorrhea, gynecomastia, hot flashes, insomnia, irritability, mastalgia, menstrual irregularities, nervousness, pruritus, rash, serum prolactin increased, sudden death, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to domperidone or any component of the formulation; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with ketoconazole",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, life-threatening tachyarrhythmias (eg, torsade de pointes), and cardiac arrest have been reported after use; these adverse effects may be precipitated in hypokalemic patients or in patients receiving other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents. Avoid use in patients with diagnosed or suspected congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated prolactin levels: May increase prolactin levels (dose-dependent response); may be asymptomatic (clinical consequence of chronically-elevated prolactin is unknown) or may present symptomatically as galactorrhea, gynecomastia, amenorrhea, or impotence (reversible upon decreasing dose or discontinuing drug).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: Use caution when administering to patients with a personal or family history of breast cancer; evidence regarding an association between chronic use of dopamine-receptor antagonists and breast cancer is limited and nonconclusive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage and/or frequency of administration may need adjusted with repeated use and/or long-term therapy. Monitor renal function regularly, particularly with long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Use with caution in patients concomitantly taking MAO inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast milk production stimulant: In 2004, the Food and Drug Administration (FDA) issued a warning recommending that domperidone not be used off-label to increase milk production in breast-feeding women due to safety concerns. Several cases of cardiac arrhythmia, cardiac arrest, and sudden death have been reported in patients receiving intravenous domperidone. The risk of similar adverse events in breast-feeding women is unknown. Domperidone is not available for any use in the United States and does not have approval for this indication in other countries.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Domperidone may enhance the QTc-prolonging effect of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Domperidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F162478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown drug-related teratogenic or primary embryotoxic effects on animal fetuses; however, comparative studies have not been done in humans. Use only when benefit outweighs potential risk in a pregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F162479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Domperidone is excreted in low concentrations in breast milk, therefore, caution should be exercised when administered to a breast-feeding woman.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F162481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agilam (VE);",
"     </li>",
"     <li>",
"      Almedon (PK);",
"     </li>",
"     <li>",
"      Andiogan (PH);",
"     </li>",
"     <li>",
"      Apuldon (HK);",
"     </li>",
"     <li>",
"      Bropasmo (PY);",
"     </li>",
"     <li>",
"      Cilroton (GR);",
"     </li>",
"     <li>",
"      Costi (TW);",
"     </li>",
"     <li>",
"      Costil (ID);",
"     </li>",
"     <li>",
"      Dome (ID);",
"     </li>",
"     <li>",
"      Domeran (ID);",
"     </li>",
"     <li>",
"      Domerdon (TH);",
"     </li>",
"     <li>",
"      Dominal (ID);",
"     </li>",
"     <li>",
"      Domp (TH);",
"     </li>",
"     <li>",
"      Domp-M (TH);",
"     </li>",
"     <li>",
"      Dompe (TW);",
"     </li>",
"     <li>",
"      Domper (PH, TW);",
"     </li>",
"     <li>",
"      Domperid (CL);",
"     </li>",
"     <li>",
"      Domperine (KP);",
"     </li>",
"     <li>",
"      Domstal (IN);",
"     </li>",
"     <li>",
"      Dosin (CN);",
"     </li>",
"     <li>",
"      Gasdol (CN);",
"     </li>",
"     <li>",
"      Gasidone (PH);",
"     </li>",
"     <li>",
"      Gastroflux (GT);",
"     </li>",
"     <li>",
"      GI Norm (PH);",
"     </li>",
"     <li>",
"      Harmetone (CO);",
"     </li>",
"     <li>",
"      Idon (PE, PY);",
"     </li>",
"     <li>",
"      Mocydone M (TH);",
"     </li>",
"     <li>",
"      Modomed (TH);",
"     </li>",
"     <li>",
"      Mogasinte (PT);",
"     </li>",
"     <li>",
"      Motidone (MY);",
"     </li>",
"     <li>",
"      Motigut (MY);",
"     </li>",
"     <li>",
"      Motilium (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CY, CZ, DE, DK, EC, EE, FR, GB, GY, HK, HN, HU, ID, IE, IL, IT, JM, LU, MX, MY, NL, NZ, PE, PH, PK, PR, PT, PY, RU, SG, SR, TR, TT, TW, UY, ZA);",
"     </li>",
"     <li>",
"      Motilium [tabs.] (PL);",
"     </li>",
"     <li>",
"      Motinorm (IN, PH);",
"     </li>",
"     <li>",
"      Nauzelin (ES, JP);",
"     </li>",
"     <li>",
"      Netaf (PE);",
"     </li>",
"     <li>",
"      Nidolium (TW);",
"     </li>",
"     <li>",
"      Ninlium (TH);",
"     </li>",
"     <li>",
"      Nordonil (PT);",
"     </li>",
"     <li>",
"      Oroperidys (FR);",
"     </li>",
"     <li>",
"      Pepridon (PH);",
"     </li>",
"     <li>",
"      Peptomet (CY);",
"     </li>",
"     <li>",
"      Peridon (IT);",
"     </li>",
"     <li>",
"      Peridys (FR);",
"     </li>",
"     <li>",
"      Rabugen (HK, MY);",
"     </li>",
"     <li>",
"      Rabugen-M (HK, MY);",
"     </li>",
"     <li>",
"      Remotil (PT);",
"     </li>",
"     <li>",
"      Seronex (MX);",
"     </li>",
"     <li>",
"      Siligaz (CN);",
"     </li>",
"     <li>",
"      Tametil (HR);",
"     </li>",
"     <li>",
"      Tilidon (ID);",
"     </li>",
"     <li>",
"      Vomerin (ID);",
"     </li>",
"     <li>",
"      Vometa (ID, PH);",
"     </li>",
"     <li>",
"      Vometa FT (MY);",
"     </li>",
"     <li>",
"      Vomitil (PK);",
"     </li>",
"     <li>",
"      Weitul (TW);",
"     </li>",
"     <li>",
"      Yaridon (ID);",
"     </li>",
"     <li>",
"      Zidon-DT (IN);",
"     </li>",
"     <li>",
"      Zilium (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Domperidone has peripheral dopamine receptor blocking properties and does not readily cross the blood-brain barrier. It increases esophageal peristalsis and increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7 hours (increases to ~21 hours in severe renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (66%); urine (31%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      da Silva OP, Knoppert DC, Angelini MM, et al, &ldquo;Effect of Domperidone on Milk Production in Mothers of Premature Newborns: A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2001, 164(1):17-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1717/abstract-text/11202662/pubmed\" id=\"11202662\" target=\"_blank\">",
"        11202662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drolet B, Rousseau G, Daleau P, et al, &ldquo;Domperidone Should Not be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(16):1883-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1717/abstract-text/11034933/pubmed\" id=\"11034933\" target=\"_blank\">",
"        11034933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dumitrascu DL and Weinbeck M, &ldquo;Domperidone Versus Metoclopramide in the Treatment of Diabetic Gastroparesis,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2000, 95(1):316-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1717/abstract-text/10638616/pubmed\" id=\"10638616\" target=\"_blank\">",
"        10638616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production.&rdquo; Available at",
"      <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm\" target=\"_blank\">",
"       file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8777 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1717=[""].join("\n");
var outline_f1_43_1717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162491\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162531\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162495\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062960\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162496\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10869539\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950036\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233709\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841022\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162472\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162471\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162529\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162475\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162459\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162526\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162463\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162478\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162498\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162479\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162467\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162481\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162458\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162474\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8777|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18516?source=related_link\">",
"      Domperidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1718="HLA-B27 homodimer";
var content_f1_43_1718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Model of the HLA-B27 heavy-chain homodimer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The &alpha;1 and &alpha;2 domains of the two HLA-B27 heavy chains are depicted in ribbon representation (copy 1 and copy 2 of the heavy chain in blue and green, respectively). The disulphide bond between the two Cys67 residues is colored red and the (putative) bound peptides are depicted schematically as yellow tubes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Bowness, P, Zaccai, N, Bird, L, Jones, EY. HLA-B27 and disease pathogenesis: new structural and functional insights. Exp Rev Mol Med. Cambridge University Press 1999. Copyright &copy; 1999 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1718=[""].join("\n");
var outline_f1_43_1718=null;
var title_f1_43_1719="Hyaluronate derivatives: Drug information";
var content_f1_43_1719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hyaluronate derivatives: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30166?source=see_link\">",
"    see \"Hyaluronate derivatives: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amvisc&reg;;",
"     </li>",
"     <li>",
"      Amvisc&reg; Plus;",
"     </li>",
"     <li>",
"      Bionect&reg;;",
"     </li>",
"     <li>",
"      Euflexxa&reg;;",
"     </li>",
"     <li>",
"      Hyalgan&reg;;",
"     </li>",
"     <li>",
"      Hylase&reg; Wound;",
"     </li>",
"     <li>",
"      Juv&eacute;derm&reg; Ultra;",
"     </li>",
"     <li>",
"      Juv&eacute;derm&reg; Ultra Plus;",
"     </li>",
"     <li>",
"      Juv&eacute;derm&reg; Ultra Plus XC;",
"     </li>",
"     <li>",
"      Juv&eacute;derm&reg; Ultra XC;",
"     </li>",
"     <li>",
"      Orthovisc&reg;;",
"     </li>",
"     <li>",
"      Perlane&reg;;",
"     </li>",
"     <li>",
"      Provisc&reg;;",
"     </li>",
"     <li>",
"      Restylane&reg;;",
"     </li>",
"     <li>",
"      Supartz&reg;;",
"     </li>",
"     <li>",
"      Synvisc-One&reg;;",
"     </li>",
"     <li>",
"      Synvisc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cystistat&reg;;",
"     </li>",
"     <li>",
"      Durolane&reg;;",
"     </li>",
"     <li>",
"      OrthoVisc&reg;;",
"     </li>",
"     <li>",
"      Suplasyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Miscellaneous;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Viscoelastic;",
"     </li>",
"     <li>",
"      Skin and Mucous Membrane Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical aid:",
"     </b>",
"     Ophthalmic (Amvisc&reg;, Amvisc&reg; Plus, Provisc&reg;): Intraocular: Depends upon procedure (slowly introduce a sufficient quantity into eye)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteoarthritis of the knee:",
"     </b>",
"     Intra-articular:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Euflexxa&reg;: Inject 20 mg (2 mL) once weekly for 3 weeks (total of 3 injections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyalgan&reg;: Inject 20 mg (2 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit with a total of 3 injections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orthovisc&reg;: Inject 30 mg (2 mL) once weekly for 3-4 weeks (total of 3-4  injections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supartz&reg;: Inject 25 mg (2.5 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit with a total of 3 injections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synvisc&reg;: Inject 16 mg (2 mL) once weekly for 3 weeks (total of 3 injections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synvisc-One&reg;: Inject 48 mg (6 mL) once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Facial wrinkles/folds: Intradermal",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Formulations differ in terms of recommended injection depth: Juvederm&reg; and Restylane&reg; are intended for mid to deep intradermal injection; Perlane&reg; is intended for injection into the deep dermis to superficial subcutis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juv&eacute;derm&reg; (all formulations): Inject as required for cosmetic result; typical treatment regimen requires 1.6 mL/treatment site; typical volume for repeat treatment is 0.7 mL/treatment site;  maximum: 20 mL/60 kg/year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perlane&reg;: Inject as required into deep dermis/superficial subcutis for cosmetic result; median total dose: 3 mL; maximum: 6 mL per treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restylane&reg;: Inject as required for cosmetic result; median total dose: 3 mL; maximum: 6 mL per treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lip augmentation: Submucosal",
"     </b>",
"     (Restylane&reg;): Adults &ge; 21 years of age: Maximum 1.5 mL per lip (upper or lower) per treatment session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin ulcers and wounds:  Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bionect&reg; cream, gel: Apply a thin layer to clean and disinfected wound or ulcer 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylase&reg; Wound gel: Apply liberally to ulcer cavity or wound and to surrounding areas once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Interstitial cystitis, refractory (unlabeled use):",
"     </b>",
"     Intravesical (unlabeled route): 40 mg in 50 mL saline intravesically (retain in bladder for at least 30 minutes) once weekly for 4 weeks, then monthly for up to 1 year in patients showing an initial response (Morales, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [sodium hyaluronate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bionect&reg;: 0.2% (25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [sodium hyaluronate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bionect&reg;: 0.2% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylase&reg; Wound: 2.5% (75 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, gel, intradermal [hyaluronic acid]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juv&eacute;derm&reg; Ultra: 24 mg/mL (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juv&eacute;derm&reg; Ultra Plus: 24 mg/mL (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juv&eacute;derm&reg; Ultra Plus XC:  Hyaluronic acid 24 mg/mL and lidocaine 0.3% (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juv&eacute;derm&reg; Ultra XC:  Hyaluronic acid 24 mg/mL and lidocaine 0.3% (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, gel, intradermal [sodium hyaluronate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perlane&reg;: 20 mg/mL (1 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restylane&reg;: 20 mg/mL (0.4 mL, 1 mL, 2 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intra-articular [hylan polymers A and B]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synvisc-One&reg;: 8 mg/mL (6 mL) [derived from or manufactured using an avian source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synvisc&reg;: 8 mg/mL (2 mL) [derived from or manufactured using an avian source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intra-articular [sodium hyaluronate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Euflexxa&reg;: 10 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyalgan&reg;: 10 mg/mL (2 mL) [derived from or manufactured using an avian source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orthovisc&reg;: 15 mg/mL (2 mL) [derived from or manufactured from bacterial source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supartz&reg;: 10 mg/mL (2.5 mL) [derived from or manufactured using an avian source]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intraocular [sodium hyaluronate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amvisc&reg;: 12 mg/mL (0.5 mL, 0.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amvisc&reg; Plus: 16 mg/mL (0.5 mL, 0.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Provisc&reg;: 10 mg/mL (0.4 mL, 0.55 mL, 0.85 mL) [contains natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intra-articular: Inject directly into the knee joint; do not inject extra-articularly or into the synovial capsule or tissues. Do not use disinfectants containing quaternary ammonium salts for skin cleansing prior to injection. Remove synovial fluid or effusion, if present, prior to injection. If used for bilateral treatment, use a separate syringe for each knee.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intradermal/Submucosal: Do not inject into a blood vessel. Following injection, slowly massage area so that it conforms to the contour of the surrounding tissue. May apply ice pack to injection site for a short period immediately after administration if treatment area swollen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juvederm&reg; is intended for mid-to-deep intradermal injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perlane&reg; is intended for injection into the deep dermis to superficial subcutis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restylane&reg; is intended for mid-to-deep intradermal injection (facial wrinkles) or submucosal injection (lip augmentation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Allow to reach room temperature prior to use. Drug may become cloudy or form a slight precipitate after administration; clinical significance unknown, but cloudy or precipitated material should be removed by irrigation or aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bionect&reg; products: Clean and disinfect wound prior to use (do not use quaternary ammonium salts due to potential for hyaluronic acid precipitation), and debride if necessary; apply a thin layer to wound or ulcer without extensive rubbing. After application, cover the area with a sterile gauze pad and if necessary, an elastic or compressive bandage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylase&reg; Wound: Clean ulcer or wound with normal saline, remove excess moisture with dry gauze, then apply gel liberally to wound or ulcer and surrounding areas. After application, cover the area with a sterile nonstick gauze pad and adhesive tape/bandage.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible:",
"     </b>",
"     Disinfectants containing quaternary ammonium salts may precipitate hyaluronic acid. Detergents and benzalkonium chloride may cause solution to have a milky appearance.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intra-articular injection: Treatment of pain in osteoarthritis in knee in patients who have failed nonpharmacologic treatment and simple analgesics (Euflexxa&reg;, Hyalgan&reg;, OrthoVisc&reg;, Supartz&reg;, Synvisc&reg;, Synvisc-One&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intradermal: Correction of moderate-to-severe facial wrinkles or folds (Juvederm&reg; [all formulations], Perlane&reg;, Restylane&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Surgical aid in cataract extraction (Amvisc&reg;, Amvisc&reg; Plus, Provisc&reg;); intraocular lens implantation (Amvisc&reg;, Amvisc&reg; Plus, Provisc&reg;); corneal transplant (Amvisc&reg;, Amvisc&reg; Plus); glaucoma filtration (Amvisc&reg;, Amvisc&reg; Plus); and retinal attachment surgery (Amvisc&reg;, Amvisc&reg; Plus)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Submucosal: Lip augmentation (Restylane&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical cream, gel: Management of skin ulcers and wounds (Bionect&reg;, Hylase&reg; Wound)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6169403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory interstitial cystitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Synvisc&reg; may be confused with Synagis&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies and/or type of local reaction may vary by formulation and site of application/injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site (intradermal): Erythema (75% to 93%), tenderness (61% to 92%), swelling (81% to 91%), pain (47% to 90%), firmness (86% to 89%), bruising (52% to 87%), lumps/bumps (56% to 83%), skin discoloration (33% to 78%), pruritus (25% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (intra-articular 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site (intra-articular): Pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (intra-articular &lt;1% to 7%), joint effusion (intra-articular 2% to 6%), tendonitis (intra-articular 2%), arthrosis (intra-articular 1%), limb pain (intra-articular 1%), parasthesia (intra-articular 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (intra-articular 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction (intradermal), angioedema (intradermal), arthritis (intra-articular), dyspnea (intradermal), rash, effusion (intra-articular), facial swelling (intra-articular), gait disturbance(intra-articular), herpetic eruptions (intradermal), hives (intra-articular), infections/abscess/necrosis (injection site; intradermal), peripheral edema (intra-articular), respiratory difficulty (intra-articular), thrombocytopenia (intra-articular; rare), urticarial (intradermal), vasovagal reaction (intradermal), visual abnormalities (intradermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Ocular (intraocular): Postoperative inflammatory reactions (iritis, hypopyon), corneal edema, corneal decompensation, postoperative increase in IOP (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hyaluronate or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intradermal/Submucosal:",
"     </b>",
"     Additional contraindications include history of anaphylaxis or presence of multiple severe allergies (Juvederm&reg; [all formulations], Perlane&reg;, Restylane&reg;); bleeding disorders (Perlane&reg;, Restylane&reg;); history of hypersensitivity to gram-positive bacterial proteins (Juvederm&reg; [all formulations], Perlane&reg;, Restylane&reg;) or lidocaine (Juvederm&reg; Ultra XC, Juvederm&reg; Ultra Plus XC); implantation/injection into sites other than the anatomical spaces recommended per labeling (Perlane&reg;, Restylane&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-articular:",
"     </b>",
"     Additional contraindications include knee joint infections or infections or skin diseases at the site of injection (Euflexxa&reg;, Hyalgan&reg;, OrthoVisc&reg;, Supartz&reg;, Synvisc&reg;, Synvisc-One&reg;); hypersensitivity to gram-positive bacterial proteins (Orthovisc&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intraocular:",
"     </b>",
"     There are no contraindications in the manufacturer&rsquo;s labeling (Amvisc&reg;, Amvisc&reg; Plus, Provisc&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection (gel): May be administered by intradermal (Juvederm&reg; [all formulations], Perlane&reg;, Restylane&reg;) or submucosal (Restylane&reg;) injection. Treatment may result in bruising/bleeding; use caution in patients receiving or recently exposed (&le;3 weeks) to thrombolytics, anticoagulants, or platelet inhibitors. Do not inject into site of active inflammation or infection. Injection into a blood vessel may cause localized superficial necrosis or may cause occlusion and lead to embolism or infarction. Use of Juvederm&reg; in patients susceptible to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied; use cautiously. Following use of Perlane&reg; and Restylane&reg;, hyperpigmentation may occur at the injection site and may last for &le;6 weeks after treatment; keloid formation may also occur. Use caution in patients receiving immunosuppressive treatment. Use in patients with prior herpetic eruption may result in reactivation. Delayed inflammatory papules may result from injections, necessitating evaluation and treatment as soft tissue infection. Laser treatment or chemical peeling may cause acute inflammatory reaction at the injection site if performed following intradermal treatment. Patient must avoid exposure to ultraviolet rays (sun and UV lamp) or severe cold until swelling and redness is resolved. Treatment site reactions usually improve in &lt;7 days (nasolabial folds) or &lt;14 days (lips). Strenuous exercise and ethanol consumption should be avoided for 24 hours following use. Supplemental &ldquo;touch up&rdquo; treatments may be required. Use in lip augmentation has not been established for products other than Restylane&reg;. Use of larger than recommended volumes per injection result in an increase in adverse events; if larger amounts are needed, follow-up treatment sessions are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection (solution): Intra-articular: Not for use in infected joints; do not use disinfectants containing quaternary ammonium salts for skin preparation (may cause precipitation of hyaluronate). Remove synovial fluid or effusion, if present, prior to injection. Do not inject extra-articularly or into synovium. Use with caution if venous or lymphatic stasis is present in the leg. Avoid strenuous activities for 48 hours after injection. Some products are produced from avian sources; use with caution in patients with hypersensitivity to avian proteins, feathers, or egg products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic: Do not overfill the anterior chamber. Postoperative increases in intraocular pressure have occurred following use of sodium hyaluronate; remove from the anterior chamber at the end of surgery and monitor intraocular pressure closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Bionect&reg; products (cream, gel): Do not use disinfectants containing quaternary ammonium salts for skin preparation (may cause precipitation of hyaluronate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Not for I.V. injection. Do not inject into blood vessels; may cause occlusion, infarction, embolism, or other systemic adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3423543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Safety for use in pregnant women has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F179371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Bionect External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (25 g): $112.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Bionect External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (30 g): $112.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Gel-One Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/3 mL (3 mL): $1170.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Perlane Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $351.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Restylane Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $319.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Synvisc Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (2 mL): $379.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Synvisc One Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (6 mL): $1137.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (DuoVisc Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-0.35 mL (1): $205.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55-0.5 mL (1): $217.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Hylira External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (340 g): $87.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amvisc Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/mL (0.5 mL): $88.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amvisc Plus Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg/mL (0.5 mL): $132.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bionect External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (20 mL): $108.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Euflexxa Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $329.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Healon GV Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mg/mL (0.55 mL): $129.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Healon Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (0.55 mL): $120.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Healon5 Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     23 mg/mL (0.6 mL): $138.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (OrthoVisc Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (2 mL): $358.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Provisc Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (0.55 mL): $147.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Supartz Intra-articular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/2.5 mL (2.5 mL): $211.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure (ophthalmic formulations); signs and symptoms of excess local inflammation or infection (intradermal formulations)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F179372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adant Dispo (ID);",
"     </li>",
"     <li>",
"      Amo Vitrax (AU, TH);",
"     </li>",
"     <li>",
"      Amvisc (NL, PL);",
"     </li>",
"     <li>",
"      Aragan (KP);",
"     </li>",
"     <li>",
"      Aragan Plus (MY);",
"     </li>",
"     <li>",
"      Artelac (GB);",
"     </li>",
"     <li>",
"      Artflex (AR);",
"     </li>",
"     <li>",
"      Arthrum (GB);",
"     </li>",
"     <li>",
"      Arthrum H (GB);",
"     </li>",
"     <li>",
"      Artz (CL);",
"     </li>",
"     <li>",
"      Atopiclair (GB);",
"     </li>",
"     <li>",
"      Atri (KP);",
"     </li>",
"     <li>",
"      Biolon (IL, KP);",
"     </li>",
"     <li>",
"      Clinitas (GB);",
"     </li>",
"     <li>",
"      Curiosin (HU);",
"     </li>",
"     <li>",
"      DisCoVisc (AU);",
"     </li>",
"     <li>",
"      Dropstar (PE);",
"     </li>",
"     <li>",
"      Durolane (ID);",
"     </li>",
"     <li>",
"      Euflexxa (GB);",
"     </li>",
"     <li>",
"      Eyecon (IL);",
"     </li>",
"     <li>",
"      Fermathron (AU);",
"     </li>",
"     <li>",
"      Gengigel (MY);",
"     </li>",
"     <li>",
"      Go-On (PH);",
"     </li>",
"     <li>",
"      Healon (BR, CN, CO, HU, IN, LU, PK, TW, ZA);",
"     </li>",
"     <li>",
"      Healon GV (AU, BR, CN, NZ, ZA);",
"     </li>",
"     <li>",
"      Healon Yellow (HK);",
"     </li>",
"     <li>",
"      Healon5 (AU, NZ);",
"     </li>",
"     <li>",
"      Healonid (AT, FR, GB);",
"     </li>",
"     <li>",
"      Hialid (HK, ID, PH, SG, TH);",
"     </li>",
"     <li>",
"      Hyal (MY);",
"     </li>",
"     <li>",
"      Hyal Forte (KP);",
"     </li>",
"     <li>",
"      Hyalein (JP);",
"     </li>",
"     <li>",
"      Hyalgan (AT, BE, BG, CZ, DK, ES, FI, FR, GB, IE, IT, SE);",
"     </li>",
"     <li>",
"      Hyaludrop (KP);",
"     </li>",
"     <li>",
"      Hylo-Comod (DE);",
"     </li>",
"     <li>",
"      Hyruan (HK, KP, TH);",
"     </li>",
"     <li>",
"      Hyruan III (TH);",
"     </li>",
"     <li>",
"      IAL (HK, ID, MY, TH);",
"     </li>",
"     <li>",
"      Iolvisc (LU);",
"     </li>",
"     <li>",
"      Jonexa (HK);",
"     </li>",
"     <li>",
"      Lacure (KP);",
"     </li>",
"     <li>",
"      Lagricel Ofteno (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Laservis (DE, MY);",
"     </li>",
"     <li>",
"      Lghyal (IN);",
"     </li>",
"     <li>",
"      Monovisc (SG);",
"     </li>",
"     <li>",
"      Orthovisc (SG);",
"     </li>",
"     <li>",
"      Osflex (ID);",
"     </li>",
"     <li>",
"      Oxyal (GB);",
"     </li>",
"     <li>",
"      Provisc (AU, LU, SG, TW, ZA);",
"     </li>",
"     <li>",
"      RenehaVis (GB);",
"     </li>",
"     <li>",
"      Suplasyn (DE, ID);",
"     </li>",
"     <li>",
"      Synocrom (HK);",
"     </li>",
"     <li>",
"      Synvisc (CH, EC, MX, PY, UY, VE);",
"     </li>",
"     <li>",
"      Viscoseal (DE, MY);",
"     </li>",
"     <li>",
"      Visiol (MY);",
"     </li>",
"     <li>",
"      Vismed (HK);",
"     </li>",
"     <li>",
"      Vivial (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium hyaluronate is a biological polysaccharide which is distributed widely in the extracellular matrix of connective tissue in man (vitreous and aqueous humor of the eye, synovial fluid, skin, and umbilical cord). Sodium hyaluronate and its derivatives form a viscoelastic solution in water (at physiological pH and ionic strength) which makes it suitable for aqueous and vitreous humor in ophthalmic surgery, and functions as a tissue and/or joint lubricant which plays an important role in modulating the interactions between adjacent tissues. Intradermal injection may decrease the depth of facial wrinkles. In the topical management of wounds and ulcers, sodium hyaluronate protects the skin against friction and abrasion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Intravitreous injection: Diffusion occurs slowly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Ophthalmic: Via Canal of Schlemm",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Constantinides C, Manousakas T, Nikolopoulos P, et al, &ldquo;Prevention of Recurrent Bacterial Cystitis by Intravesical Administration of Hyaluronic Acid: A Pilot Study,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2004, 93(9):1262-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1719/abstract-text/15180619/pubmed\" id=\"15180619\" target=\"_blank\">",
"        15180619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iavazzo C, Athanasiou S, Pitsouni E, &ldquo;Hyaluronic Acid: An Effective Alternative Treatment of Interstitial Cystitis, Recurrent Urinary Tract Infections, and Hemorrhagic Cystitis?,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2007, 51(6):1534-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1719/abstract-text/17383810/pubmed\" id=\"17383810\" target=\"_blank\">",
"        17383810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipovac M, Kurz C, Reithmayr F, et al, &ldquo;Prevention of Recurrent Bacterial Urinary Tract Infections by Intravesical Instillation of Hyaluronic Acid,&rdquo;",
"      <i>",
"       Int J Gynaecol Obstet",
"      </i>",
"      , 2007, 96(3):192-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1719/abstract-text/17280667/pubmed\" id=\"17280667\" target=\"_blank\">",
"        17280667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morales A, Emerson L, Nickel JC, et al, &ldquo;Intravesical Hyaluronic Acid in the Treatment of Refractory Interstitial Cystitis,&rdquo;",
"      <i>",
"       J Urol,",
"      </i>",
"      , 1996, 156(1):45-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1719/abstract-text/8648835/pubmed\" id=\"8648835\" target=\"_blank\">",
"        8648835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8643 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1719=[""].join("\n");
var outline_f1_43_1719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179379\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179380\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179410\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179383\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179384\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179365\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179353\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179367\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179416\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179366\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6169403\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179417\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179408\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179370\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179356\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299452\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179360\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3423543\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179385\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179371\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179363\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179372\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179355\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179369\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30166?source=related_link\">",
"      Hyaluronate derivatives: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1720="Diclofenac (topical): Pediatric drug information";
var content_f1_43_1720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=see_link\">",
"    see \"Diclofenac (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=see_link\">",
"    see \"Diclofenac (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8016814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flector&reg;;",
"     </li>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Solaraze&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Gel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Emulgel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10484166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10484149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=see_link\">",
"      see \"Diclofenac (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Actinic keratosis:",
"     </b>",
"     (Solaraze&reg; Gel): Apply 3% gel to lesions twice daily; recommended duration of therapy: 60-90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute pain (strains, sprains, contusions):",
"     </b>",
"     Patch: Apply 1 patch twice daily to most painful area of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical gel: (Voltaren&reg; Gel):",
"     <b>",
"      Note:",
"     </b>",
"     Maximum total body dose of 1% gel should not exceed 32 g per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lower extremities: Apply 4 g of 1% gel to affected area 4 times daily (maximum: 16 g per joint per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Upper extremities: Apply 2 g of 1% gel to affected area 4 times daily (maximum: 8 g per joint per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical solution: Knee: Apply 40 drops to each affected knee(s) 4 times daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8017238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solaraze&reg;: 3% (100 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg; Gel: 1% (100 g) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal, as epolamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flector&reg;: 1.3% (30s) [contains metal; 180 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pennsaid&reg;: 1.5% (150 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8016851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8016847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Flector&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pennsaid&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Voltaren&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10484150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel: Do not cover with occlusive dressings or apply sunscreens, cosmetics, lotions, moisturizers, insect repellents, or other topical medications to affected area. Do not wash area for 1 hour following application. Wash hands immediately after application (unless hands are treated joint). Avoid sunlight to exposure areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1% formulation: Use dosing card supplied with product to measure correct amount of medication. Apply gel to affected joint and rub into skin gently, making sure to apply to entire joint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     3% formulation: Apply a small amount of gel to affected area; smooth gently over lesion; usually 0.5 g of gel is used per 5 x 5 cm lesion site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical solution: Apply to clean, dry, intact skin; do not apply to eyes, mucous membranes, or open wounds. Wash hands before and after use. Apply 10 drops at a time either  directly onto knee or into hand then onto knee (helps avoid spillage). Repeat procedure until total dose has been applied. Spread evenly around knee (front, back, sides). Allow knee to dry before applying clothing. Do not shower or bathe for at least 30 minutes after applying. Do not apply heat or occlusive dressing to treated knee; protect treated knee from sunlight. Cosmetics, insect repellant, lotion, moisturizer, sunscreens, or other topical medication may be applied to treated knee once solution has dried.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patch: Apply to intact, nondamaged skin. Remove transparent liner prior to applying to skin. Wash hands after applying, handling, or removal of patch. Avoid contact with eyes. May tape down edges of patch, if peeling occurs. Should not be worn while bathing or showering. Fold used patches so the adhesive side sticks to itself; dispose of used patches out of reach of children and pets.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10484173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical solution: Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patch: Store at controlled room temperature 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep envelope sealed when not being used.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10484167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel 1%: Relief of osteoarthritis pain in joints amenable to topical therapy (eg, ankle, elbow, foot, hand, knee, wrist) in adults (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel 3%: Treatment of actinic keratosis in adults (in conjunction with sun avoidance) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical patch: Acute pain due to minor strains, sprains, and contusions (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical solution: Relief of osteoarthritis pain of the knee (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8016846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Diflucan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voltaren&reg; may be confused with traMADol, Ultram&reg;, Verelan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch (Flector&reg;) contains conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8016916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Topical gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Application site reactions: Contact dermatitis, dry skin, exfoliation, pain, paresthesia, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Reported for 3% gel:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, skin ulcer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local:  Alopecia, edema, photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular and skeletal: Arthralgia, arthrosis, back pain, CPK increased, hypokinesia, myalgia, neck pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pneumonia, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Topical solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Dermatologic: Bruising, contact dermatitis, dry skin, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, halitosis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Abnormal vision, allergic reaction, appetite decreased, asthma, back pain, blurred vision, body odor, cataract, chest pain, creatinine increased, depression, dizziness, drowsiness, dyspnea, ear pain, eczema, eye pain, facial edema, gastroenteritis, headache, laryngismus, laryngitis, leg cramps, lethargy, mouth ulceration, myalgia, neck rigidity, pain, palpitation, rectal hemorrhage, skin discoloration, ulcerative stomatitis, taste perversion, urticaria, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermal allergic reaction, dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dysgeusia, gastritis, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site dryness, irritation, erythema, atrophy, discoloration, hyperhidrosis, and vesicles, edema, itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10484168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac, any component, aspirin, or NSAIDs; patients with the &ldquo;aspirin triad&rdquo; [asthma, rhinitis (with or without nasal polyps) and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG); Do not apply to nonintact or damaged skin (eg, exudative dermatitis, eczema, infected lesions, burns, or wounds)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10484171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply topical gel or solution to open skin wounds, infected areas, mucous membranes, or exfoliative dermatitis; do not allow gel or topical solution to come in contact with eyes; do not use topical gel or solution in neonates, infants, or children. Avoid use of occlusive dressings. Avoid sunlight exposure to treated areas. Combination use with oral NSAIDs is not recommended due to increased risk of adverse reactions.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10484169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin's cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transdermal patch (used and unused) contains a large amount of medication which can cause serious adverse effects in children or pets if patch is chewed or ingested; fold used patches so the adhesive side sticks to itself; store and dispose used patches properly and out of the reach of children and pets. Transdermal patch contains conducting metal (aluminum) which may cause a burn to the skin during an MRI scan; remove patch prior to MRI; reapply patch after scan is completed. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Apply transdermal patch only to intact skin. Do not apply topical patch to the eyes, mucous membranes, open wounds, infected areas, or to exudative dermatitis. Patch should not be worn during bathing or showering.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Topical gel 3% contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; avoid use of diclofenac products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. Topical get 1% and transdermal patch contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; avoid use of dosage forms containing propylene glycol in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8016919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8016920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Diclofenac (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8017406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (topical gel 3%) / C (topical gel 1%, topical solution, topical patch) / D (topical solution &ge;30 weeks gestation) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8017407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the pregnancy category is product dependent (B topical gel 3%; C topical gel 1% and topical patch). When administered orally, diclofenac crosses the placenta. The amount of diclofenac available systemically following topical application is less in comparison to oral doses. Because it may cause prenatal constriction of the ductus arteriosus, the use of diclofenac topical late in pregnancy should be avoided. Reversible constriction of the ductus arteriosus",
"     <i>",
"      in utero",
"     </i>",
"     has been observed following topical application of diclofenac. Additional adverse fetal and maternal effects have been observed following oral use of diclofenac. Refer to the Diclofenac (Systemic) monograph for details. A registry is available for pregnant women exposed to autoimmune medications including diclofenac. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10484147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10484148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Topical gel: 6% to 10%; Topical solution: ~2% to 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Patch: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Flector&reg;: 10-20 hours; Pennsaid&reg;: 5-17 hours; Solaraze&reg; Gel: ~5 hours; Voltaren&reg; Gel: 10-14 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10484151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=see_link\">",
"      see \"Diclofenac (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid exposure to sunlight or sunlamps; notify physician if rash occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10484152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The safety of concurrent use of cosmetics, sunscreens, or other topical agents with diclofenac gel is not known.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review). American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/43/1720/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15966 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1720=[""].join("\n");
var outline_f1_43_1720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016814\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016849\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484149\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016851\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016847\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484150\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484173\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484167\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016916\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484168\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484171\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484169\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016919\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016920\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017406\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484148\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484151\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484152\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15966|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1721="Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy";
var content_f1_43_1721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/43/1721/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/43/1721/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/43/1721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque rupture and subsequent thrombus formation play a major role in the genesis of acute coronary occlusion. The introduction of fibrinolytic (thrombolytic) therapy was a major advance in the treatment of acute ST elevation myocardial infarction (STEMI), since over 90 percent of such patients have complete occlusion of the culprit artery due to thrombus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link&amp;anchor=H13452783#H13452783\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\", section on 'Plaque features responsible for acute thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, primary percutaneous coronary intervention (PCI) became the preferred reperfusion strategy for most patients with STEMI, as randomized trials have consistently shown better outcomes such as mortality and lower rates of recurrent ischemia and major complications such as intracranial hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, due in part to limited availability of timely primary PCI, fibrinolysis remains an important reperfusion strategy in many locations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the clinical use of fibrinolytic therapy in patients with STEMI. Larger discussions of the clinical trials comparing these agents to placebo or to each other, comparisons with primary percutaneous coronary intervention, markers of efficacy, and the management of failed fibrinolysis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinolytic therapy has largely not been effective in patients with a non-ST elevation MI (NSTEMI). This issue is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chest pain suggestive of an acute myocardial infarction (MI) presenting up to 12 (and possibly up to 24) hours after symptom onset and having electrocardiographic evidence of an acute MI manifested by ST elevation (&gt;1 mm in two contiguous leads after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    to rule out coronary vasospasm) that are considered to represent ischemia are candidates for reperfusion therapy with either fibrinolytic therapy or primary percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with typical and persistent symptoms in the presence of a new or presumably new left bundle branch block or a true posterior MI are also considered eligible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients who cannot receive primary PCI in a timely manner by an experienced operator should be considered for fibrinolytic therapy. All available fibrinolytic agents, compared to placebo, reduce mortality in acute STEMI. The magnitude the reduction in the risk of death in randomized trials is generally between 15 and 30 percent. The trials supporting this conclusion are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit from fibrinolytic therapy declines rapidly as the time from onset of symptoms to therapy increases beyond three hours. After twelve hours the benefit may not exceed the risk. Thus, in geographies where primary PCI is available, PCI becomes a more logical choice as the time from onset of chest pain increases. (See",
"    <a class=\"local\" href=\"#H69239847\">",
"     'Timing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our specific recommendations for choosing between these two reperfusion modalities are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link&amp;anchor=H7#H7\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'Primary PCI with stenting versus fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69239839\">",
"    <span class=\"h1\">",
"     INITIATION OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69239847\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have an acute STEMI, reperfusion therapy should",
"    <strong>",
"     not",
"    </strong>",
"    await the availability of results of cardiac biomarkers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Cardiac biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinolytic therapy should be started within 30 minutes after the diagnosis of STEMI is made, as its efficacy is declines as the time from onset of coronary occlusion to therapy increases. This recommendation is based on the following information.",
"   </p>",
"   <p>",
"    The earlier reperfusion therapy can be given, the greater the benefit that can be achieved. The survival benefit is greatest when fibrinolytic agents are administered within the first four hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/3-11\">",
"     3-11",
"    </a>",
"    ] and particularly within the first",
"    <strong>",
"     70 minutes",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although this conclusion is largely derived from clinical trials, similar findings have been noted in the community as demonstrated in the second National Registry of Myocardial Infarction (NRMI-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/9\">",
"     9",
"    </a>",
"    ]. Early therapy also has the greatest impact on infarct size and left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/7,8,11,12\">",
"     7,8,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mortality benefit is less likely with fibrinolytic therapy at 13 to 18 hours. A meta-analysis from the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group found that the absolute mortality benefit from fibrinolytic therapy at five weeks was 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be benefit in patients presenting 12 hours after symptom onset and possibly up to 24 hours if the patient has on-going or stuttering chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/13\">",
"     13",
"    </a>",
"    ]. Although most myocardial necrosis occurs early (within the first 90 to 180 minutes), the advantages of late reperfusion are presumably related to the presence of a patent infarct-related vessel, leading to improved ventricular healing, reduced infarct expansion, and greater electrical stability.",
"   </p>",
"   <p>",
"    As the length of time between patient&rsquo;s presentation to the hospital and delivery of fibrinolytic therapy (door-to-needle time) increases, the benefit from therapy decreases. Based on observations from randomized trials and from real world settings, the time from hospital arrival to drug administration (door-to-needle time) should be less than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/1,2,14\">",
"     1,2,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H12#H12\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'PCI-related delay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach to shortening the time to onset of therapy is prehospital fibrinolysis administered by emergency medical services (EMS) personnel. The potential value of prehospital fibrinolysis and its application are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=see_link\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10264?source=see_link\">",
"     \"Performance of prehospital fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to patients who present to an emergency department, the delay from patient contact to initiation of fibrinolytic therapy should be less than 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69239859\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer fibrin-specific agents to streptokinase and we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    to other fibrin-specific agents based on its generally favorable benefit to risk profile and its ease of use. The following conclusions regarding available agents have been reached from randomized trials and support our choice of tenecteplase (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       Alteplase",
"      </a>",
"      (tPA) improves survival compared to streptokinase (streptokinase is not available in the United States or Canada).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       Reteplase",
"      </a>",
"      (rPA) is comparable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"       Tenecteplase",
"      </a>",
"      (TNK-tPA) has comparable efficacy to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      , but has a lower rate of noncerebral bleeding events and is easier to use [",
"      <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/15\">",
"       15",
"      </a>",
"      ]. It is given as a single bolus and is therefore easier to administer than alteplase, which requires a bolus and then two separate drips.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred regimens for fibrinolytic agents in STEMI are presented in table form (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060528881\">",
"    <span class=\"h2\">",
"     Referral to a specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who receive fibrinolytic therapy are candidates for diagnostic coronary angiography and potential percutaneous coronary intervention. A cardiologist capable of expediting referral to the catheterization laboratory should be consulted as soon as possible after the diagnosis of STEMI is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243422\">",
"    <span class=\"h1\">",
"     USE IN SPECIFIC PATIENT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although concerns have been raised about the use of fibrinolytic therapy for each of the following patient groups, we do not believe that any of them is a contraindication to fibrinolytic therapy when primary PCI is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients with a prior myocardial infarction did not appear to benefit from fibrinolysis in GISSI-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/16\">",
"     16",
"    </a>",
"    ], other trials have noted a reduction in mortality from fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/5,17\">",
"     5,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prior CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prior coronary artery bypass graft surgery (CABG) not infrequently present with an acute STEMI (4 percent in GUSTO-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/18\">",
"     18",
"    </a>",
"    ]. The infarct-related artery in these patients was more likely to be a native coronary artery than a bypass graft (62 versus 38 percent).",
"   </p>",
"   <p>",
"    The outcome of fibrinolytic therapy in these patients was evaluated in the (United States) National Registry of Myocardial Infarction (NRMI) 2, in which 6.4 percent of almost 40,000 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    had had a prior CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/19\">",
"     19",
"    </a>",
"    ]. Prior CABG was an independent predictor of mortality with a multivariate analysis (odds ratio 1.23). There was no difference in outcome between reperfusion therapy using primary PCI or a fibrinolytic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69241755\">",
"    <span class=\"h2\">",
"     Menstruating women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some practitioners are concerned about the use of fibrinolytic agents in menstruating women. Among 12 menstruating women in GUSTO-I, there was no significant increase in severe bleeding compared to non-menstruating women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/20\">",
"     20",
"    </a>",
"    ]. There was a significant increase in moderate bleeding that was offset by the benefits of fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69242077\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus is associated with increased mortality in the setting of an acute MI. In GUSTO-I, the approximately 15 percent of patients who were diabetic had a similar benefit from fibrinolysis but a significantly higher mortality rate at 30 days (11.3 versus 5.9 percent) and one year (14.5 versus 8.9 percent) than nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=see_link\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Absolute contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute contraindications to fibrinolytic therapy include previous intracranial hemorrhage (ICH), known structural cerebral vascular lesion, known malignant intracranial neoplasm, ischemic stroke within three months, suspected aortic dissection, active bleeding or bleeding diathesis, or significant closed-head or facial trauma within three months (",
"    <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important relative contraindications include (",
"    <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poorly controlled or chronic sustained hypertension (systolic blood pressure &gt;180 mmHg) (",
"      <a class=\"graphic graphic_figure graphicRef57481 \" href=\"UTD.htm?16/22/16749\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ischemic stroke more than three months previously. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prior stroke'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Dementia or other intracranial pathology (except as above).",
"     </li>",
"     <li>",
"      Traumatic or prolonged cardiopulmonary resuscitation (&gt;10 minutes) or major surgery (within &lt;3 weeks).",
"     </li>",
"     <li>",
"      Recent (within two to four weeks) internal bleeding.",
"     </li>",
"     <li>",
"      Noncompressible vascular puncture.",
"     </li>",
"     <li>",
"      For streptokinase: prior exposure (more than five days previously) or prior allergic reaction to these agents.",
"     </li>",
"     <li>",
"      Pregnancy. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"       \"Acquired heart disease and pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Active peptic ulcer.",
"     </li>",
"     <li>",
"      Current use of anticoagulants: the higher the INR, the higher the risk of bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the contraindications described above, the value of fibrinolytic therapy is progressively diminished as the risk of intracranial hemorrhage (ICH) increases. It has been suggested that fibrinolysis has a greater potential for harm than for benefit if the risk of ICH exceeds four percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/25\">",
"     25",
"    </a>",
"    ]. While the risk of ICH in patients is difficult to determine with certainty, the predictive model developed by the Cooperative Cardiovascular Project provides one method for making such an assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with a score &ge;5 according to this predictive model have a risk of ICH of 4.11 percent (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H69243098\">",
"     'Predictors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intraocular hemorrhage from fibrinolytic therapy in patients with diabetes mellitus is rare and diabetic retinopathy should not be considered a contraindication to fibrinolytic therapy in acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7881?source=see_link&amp;anchor=H11#H11\">",
"     \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\", section on 'Fibrinolytic agents'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H69242077\">",
"     'Diabetes mellitus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Prior stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a history of a stroke were excluded from clinical fibrinolytic trials and, in clinical practice, are less likely to receive a fibrinolytic agent. Data evaluating such patients are extremely limited. In a review of 115 patients with acute MI who had a prior nonhemorrhagic cerebrovascular event, 29 were given fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/29\">",
"     29",
"    </a>",
"    ]. None of the 29 had an intracranial bleed, and these patients had a lower one-year mortality than 46 patients with a prior stroke who did not receive a fibrinolytic agent (18 versus 33 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69240952\">",
"    <span class=\"h3\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality associated with acute STEMI treated with fibrinolytic therapy increases with increasing patient age, although fibrinolytic therapy still improves outcomes compared to placebo in older individuals. However, in patients older than 75 years there is conflicting evidence about a survival benefit. The possible lack of benefit may be due to an increase in left ventricular free wall rupture.",
"   </p>",
"   <p>",
"    We do not believe age, in the absence of other risk factors of adverse outcomes with fibrinolytic therapy, is an absolute contraindication. A discussion of issues related to elderly patients who present with STEMI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\", section on 'Elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243493\">",
"    <span class=\"h1\">",
"     CONCOMITANT THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of anticoagulant and antiplatelet therapy in conjunction with fibrinolytic therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243077\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is the primary complication of fibrinolytic therapy and hemorrhagic stroke is the greatest concern. These events modestly reduce the total benefit associated with fibrinolytic therapy.",
"   </p>",
"   <p>",
"    In addition, allergic reactions can be seen in patients treated with streptokinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H2#H2\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'Streptokinase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243084\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;GUSTO-I, the largest trial of fibrinolytic therapy (streptokinase or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ), found a 1.8 percent incidence of severe bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence of moderate bleeding, defined by the need for transfusion but without hemodynamic compromise or need for an intervention, was 11.4 percent. Bleeding was most often procedure related, occurring with coronary artery bypass graft in 3.6 percent, and at the groin site of a percutaneous intervention in 2 percent. The most common site for spontaneous bleeding was the gastrointestinal tract (1.8 percent). The risk of moderate or severe bleeding appears to be greater in women than men (odds ratio 1.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243091\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of stroke and ICH were 1.2 and 0.7 percent in a non-trial community registry of 12,739 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/32\">",
"     32",
"    </a>",
"    ]. In GUSTO-I, the majority of strokes (95 percent) occurred within five days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/23,33\">",
"     23,33",
"    </a>",
"    ]. The incidence was somewhat higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Strokes associated with fibrinolysis are associated with a very high rate of mortality and morbidity. In GUSTO-I, the stroke was fatal in 41 percent and produced moderate or severe disability in 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/23\">",
"     23",
"    </a>",
"    ]. Similar findings were noted in the (United States) National Registry of Myocardial Infarction-2 registry [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243098\">",
"    <span class=\"h3\">",
"     Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for stroke have been identified from analysis of patients enrolled in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/23,24,32,34,35\">",
"     23,24,32,34,35",
"    </a>",
"    ]. In GUSTO-I, patients with a previous transient ischemic attack or stroke were at particularly high risk (5.5 and 6.9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predictive model was developed to determine the risk of ICH in patients receiving fibrinolytic therapy. The Cooperative Cardiovascular Project analyzed clinical data from 31,732 Medicare patients who received fibrinolytic therapy in 1994 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/26\">",
"     26",
"    </a>",
"    ]. Intracranial hemorrhage occurred in 455 (1.43 percent). Independent predictors of ICH included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;75 years",
"     </li>",
"     <li>",
"      Black race",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Prior history of stroke",
"     </li>",
"     <li>",
"      Systolic blood pressure &ge;160 mmHg",
"     </li>",
"     <li>",
"      Weight &le;65 kg for women or &le;80 kg for men",
"     </li>",
"     <li>",
"      International normalized ratio (INR) &gt;4 or prothrombin time (PT) &gt;24",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (versus other fibrinolytic agent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A model was developed that assigned one point for each of the independent predictors. The risk of ICH ranged from 0.69 percent for patients with 0 or 1 point to 4.11 percent for patients with &ge;5 points (",
"    <a class=\"graphic graphic_table graphicRef62946 \" href=\"UTD.htm?42/52/43851\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69243120\">",
"    <span class=\"h3\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH) should be suspected in any patient who develops sudden neurologic deterioration, a decline in level of consciousness, new headache, nausea and vomiting, or a sudden rise in blood pressure after fibrinolytic therapy, especially within the first 24 hours of treatment. The management of such patients is similar to that for patients with ICH of any cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The central steps in the early management of suspected ICH are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrinolytic, antiplatelet, and anticoagulant therapies should be discontinued.",
"     </li>",
"     <li>",
"      An emergent noncontrast head CT scan or MRI scan should be arranged.",
"     </li>",
"     <li>",
"      A neurology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurosurgery consultation should be obtained. A hematology consult may also be of value.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H549640#H549640\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Management of symptomatic intracerebral hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69241007\">",
"    <span class=\"h1\">",
"     MANAGEMENT AFTER FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with STEMI who are treated with fibrinolytic therapy and do not develop biomarker elevation should be managed similar to patients with a biomarker elevation. Coronary angiography is recommended in most patients after fibrinolytic therapy and seems reasonable in patients with aborted MI, particularly those with a large area of myocardium at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H27#H27\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful reperfusion is generally associated with significant improvement in ischemic symptoms, resolution of ST-elevation on the ECG, hemodynamic stability, and the absence of heart failure. For the patient who has responded to fibrinolytic therapy, an important issue is the role of subsequent coronary angiography and revascularization. For stable patients we suggest referral for diagnostic angiography and percutaneous coronary intervention (if indicated) compared to a strategy of medical therapy, based on evidence of better outcomes with the former. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the patient with evidence that reperfusion has been unsuccessful (failed fibrinolysis), we suggest immediate angiography, with an intent to perform rescue percutaneous intervention. Primary failure of fibrinolysis is often manifested clinically by persistent or worsening chest pain (particularly if associated with other symptoms such as dyspnea and diaphoresis), persistent or worsening ST segment elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic instability or heart failure.",
"   </p>",
"   <p>",
"    However, these clinical factors are not sufficiently predictive in all patients. As a result, in the absence of clear indications of reperfusion, the clinician must maintain a high index of suspicion for primary failure. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69236566\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of fibrinolytic therapy in patients with STEMI have been issued by American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and the European Society of Cardiology (ESC) in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/43/1721/abstract/14\">",
"     14",
"    </a>",
"    ]. Our recommendations presented below are generally in accord with those from these organizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery reperfusion with fibrinolytic therapy, when given in a timely manner, improves outcomes compared to no reperfusion therapy in patients with acute ST-elevation myocardial infarction (STEMI). However, its use is limited when reperfusion with primary percutaneous coronary intervention (PCI), performed by experienced clinicians, is readily available.",
"   </p>",
"   <p>",
"    We make the following recommendations for the use of fibrinolytic therapy in patients with acute STEMI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients within 12 hours of the onset of STEMI who have no absolute contraindications to fibrinolytic therapy and for whom reperfusion with primary PCI cannot be performed within the recommended time, we recommend fibrinolytic therapy as opposed to no reperfusion therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The decision to use fibrinolytic therapy in patients with relative contraindications needs to take into account an assessment of the benefits and risks of such therapy in the individual patient.",
"     </li>",
"     <li>",
"      For patients who present after 12 (but before 24) hours of symptom onset, and when PCI not readily available, we suggest fibrinolytic therapy as opposed to no reperfusion therapy if symptoms persist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend pre-hospital as opposed to in-hospital administration of fibrinolytic therapy for patients with acute STEMI in whom a decision has been made to not use primary percutaneous coronary intervention as the reperfusion strategy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This recommendation applies only to patients in health-care settings where prehospital administration of fibrinolytic therapy is feasible. (See",
"      <a class=\"local\" href=\"#H69239847\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irrespective of whether fibrinolytic therapy is given prehospital or in the hospital (emergency department), it should be started within 30 minutes after the diagnosis of STEMI is made. (See",
"      <a class=\"local\" href=\"#H69239847\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a fibrin-specific agent instead of streptokinase (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) and suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      instead of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       reteplase",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/1\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/2\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/3\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/4\">",
"      Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995; 25:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/5\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/6\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/7\">",
"      Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/8\">",
"      Chareonthaitawee P, Gibbons RJ, Roberts RS, et al. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation). Heart 2000; 84:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/9\">",
"      Goldberg RJ, Mooradd M, Gurwitz JH, et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). Am J Cardiol 1998; 82:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/10\">",
"      Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/11\">",
"      Gibson CM, Murphy SA, Kirtane AJ, et al. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/12\">",
"      Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 1998; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/13\">",
"      Steinberg JS, Hochman JS, Morgan CD, et al. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. Circulation 1994; 90:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/14\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/15\">",
"      Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/16\">",
"      Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/17\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/18\">",
"      Labinaz M, Sketch MH Jr, Ellis SG, et al. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. Am Heart J 2001; 141:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/19\">",
"      Peterson LR, Chandra NC, French WJ, et al. Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry of Myocardial Infarction-2). Am J Cardiol 1999; 84:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/20\">",
"      Karnash SL, Granger CB, White HD, et al. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol 1995; 26:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/21\">",
"      Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996; 28:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/22\">",
"      Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/23\">",
"      Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/24\">",
"      Aylward PE, Wilcox RG, Horgan JH, et al. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Ann Intern Med 1996; 125:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/25\">",
"      Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/26\">",
"      Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/27\">",
"      Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/28\">",
"      Ward H, Yudkin JS. Thrombolysis in patients with diabetes. BMJ 1995; 310:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/29\">",
"      Tanne D, Gottlieb S, Caspi A, et al. Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: the Israeli Thrombolytic National Survey. Arch Intern Med 1998; 158:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/30\">",
"      Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/31\">",
"      Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/32\">",
"      Huynh T, Cox JL, Massel D, et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J 2004; 148:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/33\">",
"      Mahaffey KW, Granger CB, Sloan MA, et al. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation 1998; 97:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/34\">",
"      Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/43/1721/abstract/35\">",
"      Barron HV, Rundle AC, Gore JM, et al. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2. Am J Cardiol 2000; 85:294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 55 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1721=[""].join("\n");
var outline_f1_43_1721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69239839\">",
"      INITIATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69239847\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69239859\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060528881\">",
"      Referral to a specialist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69243422\">",
"      USE IN SPECIFIC PATIENT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prior CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69241755\">",
"      Menstruating women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69242077\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Absolute contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Prior stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69240952\">",
"      - Patient age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69243493\">",
"      CONCOMITANT THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69243077\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69243084\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69243091\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69243098\">",
"      - Predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69243120\">",
"      - Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69241007\">",
"      MANAGEMENT AFTER FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69236566\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/55\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/55|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 1\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/22/16749\" title=\"figure 2\">",
"      Risk of intracranial bleed with thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/55|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/33/26140\" title=\"table 1\">",
"      Thrombolytic regimens STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23820\" title=\"table 2\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/52/43851\" title=\"table 3\">",
"      Risk factors for intracranial hemorrhage with thrombolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7881?source=related_link\">",
"      Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10264?source=related_link\">",
"      Performance of prehospital fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=related_link\">",
"      Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_43_1722="Conventional manometry and HRM with EPT";
var content_f1_43_1722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Conventional manometry and high resolution manometry with esophageal pressure topography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Manometry quantifies intraluminal esophageal and LES pressure during swallowing to detect abnormalities of peristalsis and sphincter relaxation. Conventional manometry achieved this with relatively few pressure sensors (red dots in schematic on the left and red lines in the center panel). Hence data from conventional manometry can only be accurately displayed as pressure versus time plots as in the center panel with large gaps in the esophageal lumen between pressure recording sites. High resolution manometry fills these gaps with a multitude of closely spaced pressure sensors (blue dots in the schematic on the left and white lines in the center panel). Alternatively, high resolution manometry can be displayed as a \"Clouse plot\" in esophageal pressure topography as in the right panel with pressure plotted as a continuum, interpolating values between the closely spaced sensors and displaying the pressure magnitude by color. When displayed in pressure topographic, stereotypic features of the topographic architecture of the peristaltic contraction become evident, labeled as the 1st, 2nd, 3rd, and 4th contractile segments and the proximal, middle, and distal pressure troughs. The 4th contractile segment is the LES. The onset of the swallow, timed by upper sphincter relaxation, is indicated by the vertical dotted line.",
"    <div class=\"footnotes\">",
"     UES: upper esophageal sphincter; CDP: contractile deceleration point; EGJ: esophagogastric junction; CS: contractile segment; s: second; LES: lower esophageal sphincter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1722=[""].join("\n");
var outline_f1_43_1722=null;
var title_f1_43_1723="Related features of polycythemia vera";
var content_f1_43_1723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Polycythemia vera: related clinical and laboratory features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Persistent leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent thrombocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcytosis due to iron deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized pruritus (post-bath)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unusual thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromelalgia (acral dysesthesia and erythema)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1723=[""].join("\n");
var outline_f1_43_1723=null;
var title_f1_43_1724="Steroids in childhood ITP III";
var content_f1_43_1724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical trial evidence: effectiveness of glucocorticoids, IVIg, and anti-D in initial treatment of ITP in children-III (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Authors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pop. age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Randomized treatment arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeding symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Albayrak et al",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        57",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        2 mo- 17 yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        6 mo",
"       </td>",
"       <td>",
"        M'prednisolone (po, 30 mg/kg/d x 7d)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mean platelet count on days 0-30",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Mean &gt;100K by d 4. No difference among groups",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Increased appetite and Cushingoid",
"appearance",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M'prednisolone (po, 50 mg/kg/d x 7 d)",
"       </td>",
"       <td>",
"        1 ICH",
"       </td>",
"       <td>",
"        Increased appetite and Cushingoid appearance",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIg (0.5 g/kg/d x 5 d)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        1 pt with aseptic meningitis; 2 with headache, vomiting",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; ICH: intracerebral hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George, JN, Woolf, SH, Raskob, GE, et al. Blood 1996; 88:3. Copyright &copy; 1996 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1724=[""].join("\n");
var outline_f1_43_1724=null;
var title_f1_43_1725="Common insecticides";
var content_f1_43_1725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some common examples of insecticides used to control fire ants*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chemical name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade or brand name and manufacturer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"15\">",
"        <strong>",
"         Outdoors",
"        </strong>",
"       </td>",
"       <td rowspan=\"7\">",
"        Baits",
"       </td>",
"       <td>",
"        Abamectin",
"       </td>",
"       <td>",
"        Ascend, Advance: BASF Corp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fenoxycarb",
"       </td>",
"       <td>",
"        Award: Syngenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydramethylnon",
"       </td>",
"       <td>",
"        <p>",
"         Amdro pro: BASF Corp",
"        </p>",
"        <p>",
"         ProBait: Wellmark International",
"        </p>",
"        <p>",
"         MaxForce Fire Ant Bait: Bayer",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methroprene",
"       </td>",
"       <td>",
"        Extinguish: Wellmark International",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methroprene + Hydramethlynon",
"       </td>",
"       <td>",
"        Extinguish plus: Wellmark International",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyriproxyfen",
"       </td>",
"       <td>",
"        Distance ant bait, Esteem ant bait: Valent USA Corp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indoxacarb",
"       </td>",
"       <td>",
"        Once and Done, Advion: Dupont",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Drenches, sprays, dusts, granules",
"       </td>",
"       <td>",
"        Acephate",
"       </td>",
"       <td>",
"        Orthene 75 S: Valent USA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bifenthrin",
"       </td>",
"       <td>",
"        Talstar: FMC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deltamethrin",
"       </td>",
"       <td>",
"        DeltaGard G, DeltaDust, Suspend SC: Bayer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cypermethrin",
"       </td>",
"       <td>",
"        Demon TC: Syngenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyfluthrin",
"       </td>",
"       <td>",
"        Tempo 20WP, Ultra WP, SC Ultra: Bayer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tralomethrin",
"       </td>",
"       <td>",
"        Saga WP: Bayer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambda-cyhlothrin",
"       </td>",
"       <td>",
"        Demand CS, Syngenta Prescription treatment 221 L: BASF Corp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permethrin",
"       </td>",
"       <td>",
"        Various brand names and packagers",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <strong>",
"         Indoors",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Baits",
"       </td>",
"       <td>",
"        Abamectin",
"       </td>",
"       <td>",
"        Ascend, Advance: BASF Corp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydramethylnon",
"       </td>",
"       <td>",
"        Maxforce ant bait stations, Maxforce fire ant killer bait: Bayer, Seige: BASF Corp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthoboric acid",
"       </td>",
"       <td>",
"        DRAX: Waterbury Companies Inc",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Sprays, dusts, aerosols",
"       </td>",
"       <td>",
"        Cypermethrin",
"       </td>",
"       <td>",
"        Demon TC: Syngenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deltamethrin",
"       </td>",
"       <td>",
"        DeltaDust: Bayer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boric acid",
"       </td>",
"       <td>",
"        Perma-Dust: BASF Corp",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pesticide products, registrations, and their uses are constantly changing due to federal and state restrictions. Always check the pesticide label for current recommendations and instructions before using any product.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1725=[""].join("\n");
var outline_f1_43_1725=null;
var title_f1_43_1726="Contents: General principles of palliative care";
var content_f1_43_1726=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?34/55/35709\">",
"       Palliative Care",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General principles of palliative care",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General principles of palliative care",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ethical issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/50/16165\">",
"           Ethical issues in the care of the patient with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/60/26565\">",
"           Ethics in the intensive care unit: Informed consent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24934\">",
"           Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24778\">",
"           Euthanasia and physician assisted suicide",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/2/30761\">",
"           Diagnosis of brain death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/6/29801\">",
"           Palliative care: Benefits, services, and models of care",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Geriatrics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Legal issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition/fluids/metabolic",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/34/13866\">",
"           End of life care: Stopping nutrition and hydration",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32887\">",
"           Ethics in the intensive care unit: Withholding and withdrawing life-support",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-C7BBFFDE43-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_43_1726=[""].join("\n");
var outline_f1_43_1726=null;
var title_f1_43_1727="Laser resection of bronchial carcinoid tumor";
var content_f1_43_1727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73638/brlasvap_conv.mp4?title=Laser+resection+of+bronchial+carcinoid+tumor\" style=\"width:240px;height:196px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopic laser resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 197px; height: 177px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows vaporization of a smooth walled bronchial carcinoid tumor with a Nd:YAG laser. The Nd:YAG light is invisible, but a red helium-neon aiming beam can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD, and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_43_1727=[""].join("\n");
var outline_f1_43_1727=null;
              